FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 亿腾嘉和醫藥集團有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06998 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | USD | | 0.00002 USD | | 60,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 3,000,000,000 | USD | | 0.00002 USD | | 60,000 | 本月 ...

格隆汇2月4日丨嘉和生物-B(06998.HK)公告，2月4日耗资260.4万港元回购99.8万股。 ...

嘉和生物(06998)发布公告，于2026年2月4日斥资260.4万港元回购99.75万股。 ...

智通财经APP讯，嘉和生物(06998)发布公告，于2026年2月4日斥资260.4万港元回购99.75万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 亿腾嘉和醫藥集團有限公司 呈交日期： 2026年2月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06998 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Viewpoint - The company, 嘉和生物, announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Company Actions - 嘉和生物 plans to repurchase 1 million shares at a cost of approximately 2.5564 million Hong Kong dollars [1]

Group 1 - The company, 嘉和生物 (06998), announced a share buyback of 1 million shares at a cost of approximately HKD 2.5564 million on February 3, 2026 [1]

FF305 FF305 確認 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 亿腾嘉和醫藥集團有限公司 呈交日期： 2026年2月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06998 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | ...

Group 1 - The company has changed its English name from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited" and its Chinese name from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司," effective from December 30, 2025 [1] - The change in company name has been approved by shareholders at a special meeting and certified by the Registrar of Companies in the Cayman Islands [1] - The new names have been registered in Hong Kong under the Companies Ordinance, confirming the new English and Chinese names [1] Group 2 - The company's stock trading name on the Hong Kong Stock Exchange will change from "GENOR" to "EDDING GENOR," and the Chinese stock name will change from "嘉和生物" to "亿腾嘉和," effective from February 6, 2026 [2] - The company's stock code on the Hong Kong Stock Exchange will remain "6998" despite the name changes [2] - The name changes aim to align with the expanded business of the group post-merger and better reflect the relationship with the controlling shareholder [2]

Group 1 - The company has changed its English name from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited" and its Chinese name from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司," effective from December 30, 2025 [1] - The change in company name has been approved by shareholders at a special meeting and registered with the Cayman Islands Registrar of Companies [1] - The Hong Kong Companies Registry has confirmed the new names have been registered under the Companies Ordinance [1] Group 2 - The company's stock trading name on the Hong Kong Stock Exchange will change from "GENOR" to "EDDING GENOR," and the Chinese stock name will change from "嘉和生物" to "亿腾嘉和," effective from February 6, 2026 [2] - The company's stock code on the Hong Kong Stock Exchange will remain "6998" [2] - The name changes aim to better reflect the expanded business of the group following the completion of a merger and the relationship with the controlling shareholder [2]